Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHK0F6)

Drug Name
NSC-106970 Drug Info
Synonyms
33429-83-3; Quercetin 3,4'-dimethyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxy-4H-chromen-4-one; QUERCETIN-3,4'-DIMETHYL ETHER; NSC-106970; 5,7,3'-Trihydroxy-3,4'-dimethoxyflavone; CHEBI:70008; 3,4'-dimethoxy-5,7,3'-trihydroxyflavone; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxychromen-4-one; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)-3-methoxy-chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxy-; NSC106970; 3-O-Methyltamarixetin; AC1NTGVE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5380905
ChEBI ID
CHEBI:70008
CAS Number
CAS 33429-83-3
TTD Drug ID
DMHK0F6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tubulin (TUB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [3]
Vinorelbine DMVXFYE Advanced cancer 2A00-2F9Z Approved [4]
Cabazitaxel DMPAZHC Breast cancer 2C60-2C65 Approved [5]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [6]
Ixabepilone DM2OZ3G Breast cancer 2C60-2C65 Approved [5]
Eribulin DM1DX4Q Breast cancer 2C60-2C65 Approved [5]
Epothilon DMITJRU Ovarian cancer 2C73 Phase 3 [7]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
BMS-188797 DML1CK2 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
Indibulin DM6OFJ8 Advanced sarcoma 2A60-2C35 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tubulin beta (TUBB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [11]
Albendazole DMYZ57N Echinococcus granulosus infectious disease Approved [12]
Vindesine DMVR628 Acute lymphoblastic leukaemia 2A85 Approved [13]
Taxol DMUOT9V Breast cancer 2C60-2C65 Approved [14]
Mebendazole DMO14SG Ascariasis 1F62 Approved [12]
Plinabulin DMD7L48 Non-small-cell lung cancer 2C25.Y Phase 3 [15]
Batabulin DMHWE5R Solid tumour/cancer 2A00-2F9Z Phase 2/3 [16]
ABT-751 DMNG35S Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
BNC-105 DMJC8DR Mesothelioma 2C51.2 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [20]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [21]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Selenium DM25CGV N. A. N. A. Approved [24]
Etretinate DM2CZFA Keratosis ED56 Approved [25]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [26]
Methotrexate DM2TEOL Anterior urethra cancer Approved [27]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [28]
Quercetin DM3NC4M Obesity 5B81 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [20]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [21]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [30]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Selenium DM25CGV N. A. N. A. Approved [24]
Etretinate DM2CZFA Keratosis ED56 Approved [25]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [31]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [32]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sphingomyelin phosphodiesterase (SMPD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [35]
Fluoxetine DM3PD2C Bipolar depression Approved [36]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [37]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [38]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [39]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [40]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [42]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By M-phase inducer phosphatase 3 (CDC25C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [20]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Methotrexate DM2TEOL Anterior urethra cancer Approved [27]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [47]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [48]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [49]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [50]
Testosterone DM7HUNW Hot flushes GA30 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [52]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [53]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [30]
Gefitinib DM15F0X Colon adenocarcinoma Approved [54]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [55]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Etretinate DM2CZFA Keratosis ED56 Approved [25]
Prednisone DM2HG4X Acute asthma CA23 Approved [57]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [31]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Forkhead box protein M1 (FOXM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [47]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [59]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [60]
Testosterone DM7HUNW Hot flushes GA30 Approved [51]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [61]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [1]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Post-Translational Modifications [2]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [2]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Post-Translational Modifications [2]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Gene/Protein Processing [2]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Post-Translational Modifications [2]
Sphingomyelin phosphodiesterase (SMPD1) OTZSMA54 ASM_HUMAN Gene/Protein Processing [2]

References

1 Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
2 5,7,3'-Trihydroxy-3,4'-dimethoxyflavone inhibits the tubulin polymerization and activates the sphingomyelin pathway. Mol Carcinog. 2011 Feb;50(2):113-22. doi: 10.1002/mc.20693. Epub 2010 Dec 10.
3 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
4 Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
7 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
8 Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
9 Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
10 2011 Pipeline of ZioPharm.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
13 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
14 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
15 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
16 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
17 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
18 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
19 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
20 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
21 G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
22 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
23 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
24 Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
25 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
26 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
27 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
28 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
29 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
30 Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
31 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
32 Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
33 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
34 Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
35 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
36 Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med. 2013 Jul;19(7):934-8. doi: 10.1038/nm.3214. Epub 2013 Jun 16.
37 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
38 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
39 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
40 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
41 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
42 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
43 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
44 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
45 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
46 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
47 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
48 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
49 Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
50 Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
51 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
52 Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
53 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
54 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
55 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
56 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
57 Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
58 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
59 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
60 JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
61 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.